Cargando…

Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer

This research found that the clinical outcomes (PFS, ORR, OS) of the non-platinum-based doublet regimen (docetaxel capecitabine combination) were similar to those of the platinum-based (oxaliplatin capecitabine combination) when used as first line therapy for MGC patients. BACKGROUND: Docetaxel, pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xiao-Yin, Liu, Xin, Li, Wen-Hua, Qiu, Li-Xin, Huang, Ming-Zhu, Wang, Chen-Chen, Chen, Zhi-Yu, Zhang, Wen, Feng, Wan-Jing, Guo, Wei-Jian, Zhu, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643736/ https://www.ncbi.nlm.nih.gov/pubmed/36387112 http://dx.doi.org/10.3389/fonc.2022.911160

Ejemplares similares

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
por: Chen, Jun-Bing, et al.
Publicado: (2022)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Zhou, Hong, et al.
Publicado: (2021)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
por: Hwang, Seung Jae, et al.
Publicado: (2006)

Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
por: Ungari, Andrea Queiróz, et al.
Publicado: (2017)

Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
por: Zhang, Xi, et al.
Publicado: (2022)

A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
por: Lv, Jing, et al.
Publicado: (2012)

Oncologic Nomogram for Stage I Rectal Cancer to Assist Patient Selection for Adjuvant (Chemo)Radiotherapy Following Local Excision
por: Zhao, Shutao, et al.
Publicado: (2021)

Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report
por: Lin, Zhixian, et al.
Publicado: (2019)

XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
por: Zhu, Xiao‐Dong, et al.
Publicado: (2022)

Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer
por: Zhu, Yue-Ting, et al.
Publicado: (2020)

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
por: Chen, Yizhang, et al.
Publicado: (2023)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
por: Song, Bo, et al.
Publicado: (2023)

Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients
por: Li, Pei-Jing, et al.
Publicado: (2020)

Reversible Adaptive Plasticity: A Mechanism for Neuroblastoma Cell Heterogeneity and Chemo-Resistance
por: Chakrabarti, Lina, et al.
Publicado: (2012)

Three-Tier Prognostic Index in Young Adults With Advanced Gastric Cancer
por: Chen, Guang-Liang, et al.
Publicado: (2021)

Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2019)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
por: Wang, Junhui, et al.
Publicado: (2023)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
por: Hu, Chen, et al.
Publicado: (2021)

Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials
por: Shiroiwa, T, et al.
Publicado: (2009)

Exosomes Promote Pre-Metastatic Niche Formation in Gastric Cancer
por: Gao, Jing, et al.
Publicado: (2021)

Clinical commissioning and use of the Novalis Tx linear accelerator for SRS and SBRT
por: Kim, Jinkoo, et al.
Publicado: (2012)

Evaluation of integrated respiratory gating systems on a Novalis Tx system
por: Chang, Zheng, et al.
Publicado: (2011)

The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia
por: Zhu, Hong-Hu
Publicado: (2020)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
por: Zhu, Zhe, et al.
Publicado: (2023)

Editorial: Chemo-Resistance in Gastrointestinal Cancers
por: Li, Xia, et al.
Publicado: (2022)

To Chemo or Not to Chemo… That Is the Question
por: Martin, Maria Felisa Eva B., et al.
Publicado: (2023)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
por: Yang, Szu-Chun, et al.
Publicado: (2022)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer
por: Jia, Xiya, et al.
Publicado: (2022)

Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis
por: Pan, Wen-Tao, et al.
Publicado: (2020)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wei, ZhenHeng, et al.
Publicado: (2021)

The modulation of ion channels in cancer chemo-resistance
por: Zhao, Jiayu, et al.
Publicado: (2022)

Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study
por: Li, Wenhua, et al.
Publicado: (2016)

Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein–Barr Virus Associated Gastric Cancer: A Retrospective Study
por: Xie, Tong, et al.
Publicado: (2021)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qif1ddgps0j1ut2fevd51eomeu